all report title image

Pulmonary Drugs Market, By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Others), By Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : Feb 2026
  • Code : CMI1285
  • Pages :151
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.

Market Dynamics

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.  

Key features of the study

  • This report provides in-depth analysis of pulmonary drugs market and provides market size (USD Bn) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2026 – 2033), considering 2025 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market

Market Segmentation

  • Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
    • Inhaled Corticosteroids
    • Long Acting Beta-2 Agonists
    • Antihistamines
    • Vasodilators
    • Short Acting Beta-2 Agonists
    • Others
  • Application Insights (Revenue, USD Bn, 2026 - 2033)
    • Asthma & COPD
    • Allergic Rhinitis
    • Pulmonary Arterial Hypertension
    • Cystic Fibrosis
    • Others
  • Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-Commerce
  • Regional Insights (Revenue, USD Bn, 2026 - 2033)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Sanofi SA
    • Meda Pharmaceuticals
    • Circassia Pharmaceuticals Plc.
    • AstraZenca Plc.
    • GlaxoSmithKline Plc.
    • Mallinckrodt Pharmaceuticals Plc.
    • Cheisi farmaceutici S.p.A.
    • Zambon Company S.p.A.
    • Alaxia SAS
    • Merck Sharp & Dohme Limited

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Application
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Pipeline Analysis
    • Promotional Activities and Campaigns
    • Supply Chain Analysis
    • PEST Analysis
    • Epidemiology
  4. Global Pulmonary Drugs Market, By Drug Class, 2026 – 2033, (USD Bn)
    • Overview
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Inhaled Corticosteroids
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Long Acting Beta-2 Agonists
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Antihistamines
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Vasodilators
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Short Acting Beta-2 Agonists
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Others
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
  5. Global Pulmonary Drugs Market, By Application, 2026 – 2033, (USD Bn)
    • Overview
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Asthma & COPD
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Allergic Rhinitis
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Pulmonary Arterial Hypertension
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Cystic Fibrosis
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Others
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
  6. Global Pulmonary Drugs Market, By Distribution Channel, 2026 – 2033, (USD Bn)
    • Overview
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Hospital Pharmacies
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • Retail Pharmacies
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
    • E-Commerce
      • Market Share Analysis, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, 2021 - 2033
      • Segment Trends
  7. Global Pulmonary Drugs Market, By Region, 2026 – 2033, (USD Bn)
    • Introduction
      • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
      • Y-o-Y Growth Analysis, For Region, 2021 - 2033
    • North America
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
        • U.S.
        • Canada
    • Latin America
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
        • UK
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
      • Y-o-Y Growth Analysis, For Country, 2021 - 2033
      • Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
      • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Meda Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Circassia Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AstraZeneca Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Mallinckrodt Pharmaceuticals Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Cheisi Farmaceutici S.p.A
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Zambon Company S.p.A
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Alaxia SAS
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Merck Sharp & Dohme Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.